Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Vaccines

Free Subscription 10.11.2025 2 BMJ 2 Infect Immun 3 J Virol 1 JAMA 1 N Engl J Med 1 PLoS Med 5 PLoS One 4 Proc Natl Acad Sci U S A 1 Science 17 Vaccine 1 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMJ

1. WISE J
   Covid-19: Major study compares myocarditis risk in children after vaccination or infection.
   BMJ. 2025;391:r2330.
   PubMed        
   
   
2. WISE J
   RFK Jr urges world to follow US's lead on mercury in vaccines.
   BMJ. 2025;391:r2335.
   PubMed        
   
   

   
   Infect Immun

3. ZHANG W, Sack DA
   Recent progress in enterotoxigenic Escherichia coli vaccine research and development.
   Infect Immun. 2025 Nov 6:e0036825. doi: 10.1128/iai.00368.
   PubMed         Abstract available
   
   
4. HEINZEN RA, Pierce KN, Voth DE, Stenos J, et al
   Control of human Q fever by vaccination: the journey to Q-VAX and beyond.
   Infect Immun. 2025 Nov 6:e0028025. doi: 10.1128/iai.00280.
   PubMed         Abstract available
   
   

   
   J Virol

5. SUN Y, Xu S-J, Zhou Y, Zhang Y, et al
   A glycoprotein D-targeted lipid nanoparticle-encapsulated mRNA vaccine elicits strong protective immunity against pseudorabies virus.
   J Virol. 2025 Nov 6:e0147225. doi: 10.1128/jvi.01472.
   PubMed         Abstract available
   
   
6. IRELAND J, Myers D, Huang C, Allen C, et al
   Vaccination protects against COVID-associated pulmonary fibrin deposition.
   J Virol. 2025 Nov 6:e0063325. doi: 10.1128/jvi.00633.
   PubMed         Abstract available
   
   
7. CHANG LA, Yeung ST, Warang P, Noureddine M, et al
   Transient lung eosinophilia during breakthrough influenza infection in vaccinated mice is associated with protective and balanced Type 1/2 immune responses.
   J Virol. 2025 Nov 5:e0096525. doi: 10.1128/jvi.00965.
   PubMed         Abstract available
   
   

   
   JAMA

8. PANT S
   New COVID-19 Vaccination Guidelines for Immunocompromised Individuals.
   JAMA. 2025 Nov 7. doi: 10.1001/jama.2025.19727.
   PubMed        
   
   

   
   N Engl J Med

9. MALKIN E, Zaric M, Kieh M, Baden LR, et al
   Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.
   N Engl J Med. 2025;393:1807-1818.
   PubMed         Abstract available
   
   

   
   PLoS Med

10. JIAO B, Sato R, Mak J, Patenaude B, et al
    Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling study.
    PLoS Med. 2025;22:e1004764.
    PubMed         Abstract available
    
    

    
    PLoS One

11. KOSTRZEWA M, Sadat Seyyedsalehi M, Godono A, Collatuzzo G, et al
    Cancer Prevention at Work (CPW) project: Rationale, framework and research protocol.
    PLoS One. 2025;20:e0335752.
    PubMed         Abstract available
    
    
12. POWELL A, Van Hout MC, Connors D, Montgomery C, et al
    A thematic analysis of flu vaccine hesitance in ethnically minoritised communities in Liverpool.
    PLoS One. 2025;20:e0333602.
    PubMed         Abstract available
    
    
13. AYOUNI I, Githaiga JN, Amponsah-Dacosta E, Kagina BM, et al
    Adapting the WHO Behavioural and Social Drivers of Vaccination (BeSD) tools and Vaccination Attitudes Examination (VAX) scale for pregnant women in South Africa: Insights from a mixed-methods pilot study.
    PLoS One. 2025;20:e0334854.
    PubMed         Abstract available
    
    
14. FEKRI M, Bolhassani A, Movahedi M, Rahmati F, et al
    Simultaneous efficacy of IL-15 and the HSP70 fragments in increasing immunostimulatory effects of a HIV-1 DNA vaccine candidate against SCR HIV-1.
    PLoS One. 2025;20:e0336042.
    PubMed         Abstract available
    
    
15. LI C, Zhu Y, Qi X, Chai Z, et al
    Design of a multi-epitope recombinant BCG vaccine targeting Brucella OMP31, LptE and VirB2 in immunoinformatics approaches.
    PLoS One. 2025;20:e0334843.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

16. TATARA AM, Lightbown S, Kang S, Jung WH, et al
    Scaffold vaccination for prevention of orthopedic device infection.
    Proc Natl Acad Sci U S A. 2025;122:e2409562122.
    PubMed         Abstract available
    
    
17. CHO E, Davis MA, Nowak JA, Izzo M, et al
    Modulating antigen processing through metal-organic frameworks to bias adaptive immunity.
    Proc Natl Acad Sci U S A. 2025;122:e2409555122.
    PubMed         Abstract available
    
    
18. SONG K, Nguyen DC, Wang Y, Jokonya S, et al
    Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.
    Proc Natl Acad Sci U S A. 2025;122:e2409978122.
    PubMed         Abstract available
    
    
19. HAAS CM, Jasti N, Dosey A, Allen JD, et al
    From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks.
    Proc Natl Acad Sci U S A. 2025;122:e2409566122.
    PubMed         Abstract available
    
    

    
    Science

20. ZHANG H, Liu H, Xu Y, Huang H, et al
    Deep generative models design mRNA sequences with enhanced translational capacity and stability.
    Science. 2025 Aug 28:eadr8470. doi: 10.1126/science.adr8470.
    PubMed         Abstract available
    
    

    
    Vaccine

21. LIU D, Zhang Y, Lei J, Li J, et al
    Influenza, pneumococcal, COVID-19 vaccine willingness and uptake with influencing factors in 38,184 chinese older adults in 2022: a nationwide cross-sectional study.
    Vaccine. 2025;68:127961.
    PubMed         Abstract available
    
    
22. NETT RJ, Brault AC, Lambert AJ, Agnihothram S, et al
    Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development.
    Vaccine. 2025;68:127938.
    PubMed         Abstract available
    
    
23. SHARFF KA, Haslam A, Nealon J
    COVID-19 vaccine variant target: how should we choose?
    Vaccine. 2025;68:127917.
    PubMed        
    
    
24. DE MELO ARAUJO AC, Frugoli AG, de Sena Goncalves JE, Percio J, et al
    Corrigendum to "Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review" [Vaccine 66 (2025) 127850].
    Vaccine. 2025;68:127929.
    PubMed        
    
    
25. HAMASHIMA Y, Breheny K, Davies SR, Dawson S, et al
    A synthesis of economic data from randomized trials of recipient-focused interventions to increase vaccine uptake.
    Vaccine. 2025;68:127906.
    PubMed         Abstract available
    
    
26. WU Y, Ren B, Gao X, Li N, et al
    Evaluation of the immunization effects of needle-free injection for four common porcine vaccines.
    Vaccine. 2025;68:127943.
    PubMed         Abstract available
    
    
27. SENDERS S, Korbal P, Kline M, Tamimi N, et al
    Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants.
    Vaccine. 2025;68:127916.
    PubMed         Abstract available
    
    
28. RHYNE PW, Sunshine J, Hogrefe W, Roscia G, et al
    Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines.
    Vaccine. 2025;68:127896.
    PubMed         Abstract available
    
    
29. THAWEETHAI T, Gross RS, Pant DB, Rhee KE, et al
    Preventive effect of vaccination on long COVID in adolescents with SARS-CoV-2 infection.
    Vaccine. 2025;68:127907.
    PubMed         Abstract available
    
    
30. BATMUNKH T, Neal EFG, Amraa O, Mazarakis N, et al
    Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.
    Vaccine. 2025;66:127840.
    PubMed         Abstract available
    
    
31. NAKAHIRA A, Iwaoka H, Sato K, Ishizuka S, et al
    NKT cell-dependent PspA-specific IgA production caused by mucosal administration of a novel nanoparticle pneumococcal vaccine.
    Vaccine. 2025;68:127911.
    PubMed         Abstract available
    
    
32. YU SL, Chung NH, Chen YC, Ho HM, et al
    Natural killer T cells play a significant role in preventing Coxsackievirus A10 infection through an adeno-based vaccine expressing enterovirus-like particles.
    Vaccine. 2025;68:127909.
    PubMed         Abstract available
    
    
33. SALINES M, Andraud M, Scoizec A, Schmitz A, et al
    To what extent may the duck population be protected after vaccination against highly pathogenic avian influenza? Contributions from a modelling approach and French field data.
    Vaccine. 2025;68:127905.
    PubMed         Abstract available
    
    
34. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) meeting, virtual gathering, 1-5 September 2025.
    Vaccine. 2025;68:127903.
    PubMed         Abstract available
    
    
35. MEMIRIE ST, Teka T, Mekasha A, Alemayehu T, et al
    Prioritization of future new vaccines introduction: The experience of the Ethiopian National Immunization Technical Advisory Group.
    Vaccine. 2025;68:127932.
    PubMed         Abstract available
    
    
36. MAHAJAN M, Martin LB, Gaurav K, Suri RK, et al
    Adaptive clinical trial designs for rapid vaccine development: Developing country vaccine manufacturers' perspective.
    Vaccine. 2025;68:127890.
    PubMed         Abstract available
    
    
37. MORRIS SE, O'Halloran A, Sundaresan D, Dawood FS, et al
    Heterogeneity in seasonal influenza vaccination opportunity and disease risk during pregnancy and in infants <6 months.
    Vaccine. 2025;68:127887.
    PubMed         Abstract available
    
    

    
    Virus Res

38. CAO W, Li J, Yang F, Zhu Z, et al
    Comparative investigation into the immune efficiency of the single intradermal and intramuscular delivery of foot-and-mouth disease inactivated vaccine in swine.
    Virus Res. 2025 Nov 3:199656. doi: 10.1016/j.virusres.2025.199656.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.